16:02:55 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning PHO 0.00 NOK
2024-05-23 Årsstämma
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-09 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-05-04 X-dag ordinarie utdelning PHO 0.00 NOK
2023-05-03 Årsstämma
2023-02-24 Bokslutskommuniké 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-04-29 X-dag ordinarie utdelning PHO 0.00 NOK
2022-04-28 Årsstämma
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-07-28 Extra Bolagsstämma 2021
2021-05-21 X-dag ordinarie utdelning PHO 0.00 NOK
2021-05-20 Årsstämma
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-03 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-11 X-dag ordinarie utdelning PHO 0.00 NOK
2020-06-10 Årsstämma
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-07 Kvartalsrapport 2019-Q2
2019-06-19 Extra Bolagsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-05-10 X-dag ordinarie utdelning PHO 0.00 NOK
2019-05-09 Årsstämma
2019-02-27 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-23 Kvartalsrapport 2018-Q1
2018-05-11 X-dag ordinarie utdelning PHO 0.00 NOK
2018-05-09 Årsstämma
2018-02-27 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-04-28 X-dag ordinarie utdelning PHO 0.00 NOK
2017-04-27 Årsstämma
2017-02-15 Bokslutskommuniké 2016
2016-11-15 Kvartalsrapport 2016-Q3
2016-08-23 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-29 X-dag ordinarie utdelning PHO 0.00 NOK
2016-04-28 Årsstämma
2016-02-11 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-02 X-dag ordinarie utdelning PHO 0.00 NOK
2015-04-30 Årsstämma
2015-02-12 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-28 X-dag ordinarie utdelning PHO 0.00 NOK
2014-05-27 Årsstämma
2014-05-07 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-23 X-dag ordinarie utdelning
2013-05-22 Årsstämma
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-05-10 Årsstämma
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-27 Årsstämma
2011-02-17 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-19 Bokslutskommuniké 2009
2009-11-26 X-dag bonusutdelning

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2023-12-21 08:00:00

Oslo, Norway, 20 December 2023 - Photocure ASA (the "Company") (OSE: PHO) cancels up to 1,400,428 options and has subsequently re-issued 399,000 options to employees. Up to 257,214 additional options are expected to be re-issued to employees in the near term, resulting in a net reduction of up to 744,214 options. 508,153 cancelled options were already vested, while all newly granted options will be replaced with options that are subject to a reset three-year vesting period, fully resetting the vesting period.

A total of 399,000 share options, which vest over a three-year period, equal to 1.5% of total shares issued in the Company, have been granted at an exercise price of NOK 61.03. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price. The Company expects to receive further acceptances on cancellation and re-issue of options and will disclose the final number together with the number of options granted on the same terms as set out herein once this process is completed. The net effect will be a full reset of the three-year vesting period and a net reduction in options outstanding of up to 744,214.

The options are granted in accordance with Photocure's long term incentive program and the Company's guidelines for remuneration of senior executives and other employees, as approved by Photocure's annual general meeting held 28 April 2022. The share option program and properties of the options are further described in the remuneration guidelines.

Of the total grant the following was granted to primary insiders:
  • Dan Schneider, President and Chief Executive Officer, 132,500 options.
  • Erik Dahl, Chief Financial Officer, 78,750 options.
  • Geoffrey Coy, Vice President and General Manager of North America Operations, 66,250 options.
  • Susanne Strauss, Vice President and General Manager of Europe Operations, 66,250 options.
  • Anders Neijber, Vice President Global Medical Affairs and Clinical Development, 44,000 options.
  • Anja Gossens-von der Heidt, Head of Global Human Resources, 11,250 options.

Primary insider notifications pursuant to the market abuse regulation article 19 are attached.

For further information, please contact:

Erik Dahl
Chief Financial Officer
Email: ed@photocure.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Erik Dahl, CFO, Photocure ASA, on 21 December 2023 at 08:00 CET.